Systematisierte Depigmentierung bei strahlenbehandelten Melanomen

Kärcher, K H

doi:10.1159/000255320

Cited by 9 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In Europe, several studies and case histories were published on this subject in the late 1960s [3][4][5][6], Since both vitiligo and melanoma represent disorders involving melano cytes, more recently there has been much speculation on possible clinical connections especially in regard to inimunologic factors [ 17,18.36]; even so. there is no direct evi dence in humans for such a relationship.…”

Section: Discussionmentioning

confidence: 99%

“…In order to assess the possible correlation of vitiligo with malignant melanoma as suggested by others [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18], specific emphasis has been placed on the time of onset of both diseases. Eleven patients had their vitiligo before diagnosis of malignant melanoma, whereas 11 patients developed depigmentation after diagnosis of their tumors including 1 patient with an unknown primary tumor who developed vitiligo and metastasis synchronously.…”

Section: Types and Temporal Distribution O F Vitiligomentioning

confidence: 99%

“…Vitiligo or vitiligo-like leukoderma associated with malignant melanoma has been observed by several inves tigators over the past [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18], However, the relative rates of this phenomenon have been quite controversial ranging from 1.4 [7] to 20% [ 19], The association of the two disorders has been well documented in animals (i.e. Lippizanerand Arabian horses, and in Sinclair swine) [20.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Vitiligo and Cutaneous Melanoma

Schallreuter

Levenig²,

Berger³

1991

Dermatology

View full text Add to dashboard Cite

The examination of 623 melanoma patients in North Germany yielded the depigmentation disorder vitiligo in 23 cases (i.e. 3.7%). In 11 patients, the disease preceded their tumor, whereas in 11 patients, vitiligo developed after diagnosis of primary and/or metastatic melanoma into the regional lymph nodes. In 1 case the onset of melanoma in relation to the tumor remained undefined. The prevalence of vitiligo increased with tumor risk factors based on tumor thickness and anatomical site of tumor location (i.e. for low risk 1.75% intermediate risk 5.2% and high risk 5.8%). A comparison of the prevalence of vitiligo to the normal population of Northwestern Europe (i. e. 0.38–0.57%) showed a 7- to 10-fold increase for the patients with melanoma. A reverse analysis of the data yielded a 180-fold higher prevalence of melanoma in the group of patients with vitiligo. These results strongly support a more thorough examination of patients with vitiligo for primary melanoma.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Types and Temporal Distribution O F Vitiligomentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Vitiligo and Cutaneous Melanoma

Schallreuter

Levenig²,

Berger³

1991

Dermatology

View full text Add to dashboard Cite

show abstract

“…Surgical treatment has been the standard of care for nearly 150 years [12]. One of the earliest case-based observations linking vitiligo and melanoma was published in 1953, when a patient with a ‘melanosarcoma’ developed depigmented lesions [13], followed by a report in 1960 noting systemic depigmentation in a melanoma patient treated with radiation therapy [14]. Four years later, Burdick and Hawk reported regression of cutaneous and visceral lesions – concurrent with the development of vitiligo – in a metastatic melanoma patient treated with Vaccinia virus [15].…”

Section: Melanoma and Vitiligo: A History Of Clinical Correlationsmentioning

confidence: 99%

New Perspectives on the Role of Vitiligo in Immune Responses to Melanoma

Byrne

Turk

2011

Oncotarget

View full text Add to dashboard Cite

Melanoma-associated vitiligo is the best-studied example of the linkage between tumor immunity and autoimmunity. Although vitiligo is an independent positive prognostic factor for melanoma patients, the autoimmune destruction of melanocytes was long thought to be merely a side effect of robust anti-tumor immunity. However, new data reveal a key role for vitiligo in supporting T cell responses to melanoma. This research perspective reviews the history of melanoma-associated vitiligo in patients, the experimental studies that form the basis for understanding this relationship, and the unique characteristics of melanoma-specific CD8 T cells found in hosts with vitiligo. We also discuss the implications of our recent findings for the interpretation of patient responses, and the design of next-generation cancer immunotherapies.

show abstract